免疫检查点抑制剂新辅助治疗Ⅰ-Ⅲ期非小细胞肺癌的临床研究进展  

Clinical research progress of immune checkpoint inhibitor neoadjuvant treatment of stage Ⅰ-Ⅲ non-small cell lung cancer

作　　者：邵雅楠 张悦[1] 乔欣怡 吴云娇 王萌[1] SHAO Yanan;ZHANG Yue;QIAO Xinyi;WU Yunjiao;WANG Meng(Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院,黑龙江哈尔滨150001

出　　处：《现代肿瘤医学》2024年第17期3354-3359,共6页Journal of Modern Oncology

摘　　要：非小细胞肺癌是全球癌症相关死亡的主要原因之一,尽管完整的手术切除为这部分患者提供了最佳的治愈机会,但仍有很多的患者术后复发,通常需要进行术前的新辅助治疗。非小细胞肺癌的新辅助治疗近年来进展缓慢,随着针对局部晚期和转移性肺癌的免疫检查点抑制剂的出现,其应用范围逐步从晚期扩大到术前治疗,代表了非小细胞肺癌治疗手段的逐渐增加。为了评估其在新辅助治疗中的疗效和安全性,进行相关的临床研究变得越来越重要。该文综述了Ⅰ-Ⅲ期非小细胞肺癌中免疫检查点抑制剂新辅助治疗的临床研究进展,相关的疗效评价标准和预测性生物标志物的探索以及今后亟待解决的问题。Non-small cell lung cancer is one of the leading causes of cancer-related deaths worldwide.Although complete surgical resection provides the best chance of cure for these patients,many of patients will relapse after surgery.Usually requires neoadjuvant treatment before surgery.The neoadjuvant treatment of non-small cell lung cancer has progressed slowly in recent years.With the emergence of immune checkpoint inhibitors for locally advanced and metastatic lung cancer,its application range has gradually expanded from advanced to preoperative treatment,representing the treatment of non-small cell lung cancer a gradual increase in means.In order to evaluate its efficacy and safety in neoadjuvant therapy,it is becoming more and more important to conduct related clinical studies.This article reviews the clinical research progress of immune checkpoint inhibitor neoadjuvant therapy in stage Ⅰ-Ⅲ non-small cell lung cancer,the exploration of related efficacy evaluation standards and predictive biomarkers,and the problems that need to be solved in the future.

关 键 词：非小细胞肺癌 新辅助治疗 免疫检查点抑制剂 主要病理缓解 完全病理缓解 

分 类 号：R734.2[医药卫生—肿瘤]